Myrtelle Raises $30.5M Series B-II to Advance Gene Therapies for Rare Neurodegenerative Disorders
Myrtelle, a clinical‑stage gene therapy company focused on developing transformative treatments for rare neurodegenerative and genetic disorders, has recently completed a major Series B‑II funding round of approximately $30.53 million, reflecting growing investor confidence in its innovative approach to addressing diseases with few or no treatment options. The Series B‑II financing, which closed late in December 2025, expands the company’s financial runway as it continues to advance its lead clinical program targeting Canavan disease and builds momentum across its broader pipeline of gene therapy assets.
Founded in 2020 and headquartered in Wakefield, Massachusetts, Myrtelle leverages proprietary adeno‑associated virus (AAV) vector technology to develop gene therapies that directly target key cell types affected in central nervous system (CNS) disorders. The company’s lead candidate, rAAV‑Olig001‑ASPA (MYR‑101), is engineered to target oligodendrocytes—the myelin‑producing cells that are compromised in Canavan disease—with the goal of restoring the function of the ASPA enzyme and supporting normal brain development. This program has garnered several regulatory designations, including Fast Track, Rare Pediatric Disease, and Orphan Drug status from the U.S. Food and Drug Administration, as well as orphan drug designation and advanced therapy classification from the European Medicines Agency, underscoring its potential to address a critical unmet medical need.
The lead investor in the latest financing round was Panacea Venture, a life sciences venture capital firm dedicated to backing companies targeting high‑impact therapeutic innovation across rare diseases, oncology, and regenerative medicine. Panacea Venture has supported Myrtelle through multiple stages of growth, including prior rounds, and its continued participation underscores a long‑term commitment to advancing the company’s pipeline and commercial prospects.
Myrtelle has raised capital across multiple funding rounds since its founding, and while details on earlier financing have varied, available information suggests the company has raised tens of millions in total to support clinical development, vector manufacturing, and pipeline expansion. Debt financing rounds in 2024 and 2025 helped provide intermediate capital between equity raises, contributing to a solid financial foundation as the company pushed its Canavan disease program into later‑stage development.
The capital from the recent Series B‑II round is being directed toward advancing MYR‑101 through clinical development, supporting ongoing regulatory interactions, and bolstering manufacturing capabilities critical to future trial and commercial scale‑up. Investments in manufacturing infrastructure and strategic partnerships are central to Myrtelle’s strategy, as the company works to ensure robust supply chains for its gene therapy products and streamline production of recombinant AAV vectors.
Myrtelle’s funding and clinical progress come at a time when gene therapy is increasingly viewed as a frontier in treating rare genetic and neurodegenerative diseases that have historically lacked effective options. Canavan disease, a fatal childhood leukodystrophy caused by mutations in a gene critical for myelin production, typically leads to severe neurological impairment and early mortality. By targeting the underlying genetic cause of the disorder, MYR‑101 represents a first‑in‑class therapeutic candidate that could transform outcomes for affected patients.
Beyond its lead program, Myrtelle has expanded its research and development efforts into additional white matter disorders and related genetic conditions. These include preclinical initiatives addressing diseases such as Pelizaeus‑Merzbacher disease, where proprietary vector technology is being leveraged to deliver gene‑silencing or gene‑replacement approaches aimed at restoring normal cellular function. Such pipeline diversification reflects the company’s ambition to apply its platform broadly across indications involving oligodendrocyte dysfunction.
In parallel with advancing its internal programs, Myrtelle has entered strategic collaborations to enhance its scientific and manufacturing capabilities. Partnerships with organizations specializing in viral vector development and GMP production help strengthen the company’s ability to scale both research and clinical‑grade manufacturing as it prepares for larger trials and potential commercialization. These alliances reinforce Myrtelle’s positioning within the broader gene therapy ecosystem and support its operational growth.
Leadership at Myrtelle emphasizes a long‑term commitment to translating deep scientific innovation into life‑changing therapies for patients and families affected by rare diseases, particularly those impacting the central nervous system. The completion of the Series B‑II financing represents a major step toward achieving these goals, reinforcing the company’s capacity to navigate complex regulatory pathways, expand its pipeline, and bring novel genetic medicines closer to clinical reality.
As Myrtelle continues to advance its gene therapy programs with the support of dedicated investors like Panacea Venture and strategic partners across the biotechnology landscape, the company remains focused on fulfilling its mission to develop transformative treatments for devastating disorders with little or no existing therapeutic options.
